• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Anticoagulation in special patient populations with atrial fibrillation
Herz. 2021 Jul 5. doi: 10.1007/s00059-021-05042-1. Online ahead of print.ABSTRACTAnticoagulation in patients with atrial fibrillation (AF) should be guided by considerations of the risk of thromboembolism, stroke, and bleeding as well as the patient's preference. Well-recognized scores have been developed to help the clinician in daily risk assessment, but there are several special patient populations for whom scores are not developed or validated. Furthermore, these patients were not adequately represented in the pivotal randomized trials for non-vitamin K antagonist oral anticoagulants (NOACs). In patients with cancer, t...
Source: Herz - July 5, 2021 Category: Cardiology Authors: Laura Ueberham Gerhard Hindricks Source Type: research

Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation
Circ J. 2021 Jun 5. doi: 10.1253/circj.CJ-21-0399. Online ahead of print.ABSTRACTStroke prevention is the cornerstone of management of atrial fibrillation (AF), and non-vitamin K antagonist oral anticoagulants (NOACs) are commonly prescribed. Because routine monitoring of anticoagulant effects of NOACs is not necessary, appropriate dosing following the criteria of each NOACs defined in pivotal randomized trials is important. Real-world data demonstrate that underdosing NOACs is associated with a higher risk of ischemic stroke without a lower risk of major bleeding. Furthermore, renal function of AF patients should be asses...
Source: Circulation Journal - June 7, 2021 Category: Cardiology Authors: Wen-Han Cheng Yi-Hsin Chan Jo-Nan Liao Ling Kuo Shih-Ann Chen Tze-Fan Chao Source Type: research

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer.
CONCLUSIONS: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year after cancer diagnosis. PMID: 29671285 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - April 21, 2018 Category: Cardiology Tags: Korean Circ J Source Type: research

Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey
In conclusion, the complex clinical condition in frail patients presenting with arrhythmias warrants an integrated multidisciplinary approach both for the management of rhythm disturbances and for the decision on using CIEDs.
Source: Europace - October 10, 2017 Category: Cardiology Source Type: research

Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
Learning objectives Understand the importance of venous thrombosis in cardiovascular medicine. Appreciate the mode of action of different oral anticoagulants. Recall the uses, risks and benefits of each non-vitamin K antagonist oral anticoagulants. Introduction Thrombosis is the common pathophysiology responsible for ischaemic heart disease, ischaemic stroke and venous thromboembolism (VTE), and a major contributor to the global disease burden.1 This effect is markedly more pronounced by considering the view that cancer is also a thrombotic disease.2 3 Cardiovascular disease (CVD, manifesting as acute coronary syndromes, m...
Source: Heart - June 5, 2016 Category: Cardiology Authors: Blann, A. D., Lip, G. Y. H. Tags: Education in Heart, Drugs: cardiovascular system, Acute coronary syndromes, Venous thromboembolism, Epidemiology Source Type: research

Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
Abstract The direct oral anticoagulants (DOACs) represent a major advance in oral anticoagulant therapy and have replaced the vitamin K antagonists as the preferred treatment for many indications. By simplifying long-term anticoagulant therapy and improving its safety, the DOACs have the potential to reduce the global burden of thrombosis. Postmarketing studies suggest that the favorable results achieved with DOACs in the randomized controlled trials can be readily translated into practice, but highlight the need for appropriate patient, drug and dose selection, and careful follow-up. Leveraging on their success t...
Source: Circulation Research - April 28, 2016 Category: Cardiology Authors: Chan NC, Eikelboom JW, Weitz JI Tags: Circ Res Source Type: research

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study
Conclusion: Medical and social variables were associated with prescription of NOAC. Major bleeding, hemorrhagic stroke, university education, and higher glomerular filtration rate were more frequent among patients under NOAC. On the contrary, patients with history of cancer or bradyarrhythmias more frequently received VKA.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - February 24, 2016 Category: Cardiology Authors: Moreno-Arribas, J., Bertomeu-Gonzalez, V., Anguita-Sanchez, M., Cequier, A., Muniz, J., Castillo, J., Sanchis, J., Roldan, I., Marin, F., Bertomeu-Martinez, V., on behalf of the investigators of the FANTASIIA study Tags: Clinical Studies Source Type: research

Pages: 1  2